Deerfield Management
Leading healthcare investment firm dedicated to advancing healthcare through investment, information, and philanthropy. Invests across the full lifecycle of healthcare companies from seed to post-IPO, with deep expertise in drug development.
Website
https://www.deerfield.comLocation
New York, USA
Founded
1994
AUM
$10B+
Investment Range
$10M - $200M
Portfolio Companies
3
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth
Investment Thesis
Deerfield invests across the healthcare ecosystem, from early-stage therapeutics to established biopharma companies. They combine deep scientific expertise with financial discipline to identify companies developing transformative therapies. Their full-lifecycle approach allows them to support companies from seed funding through commercial success.
Team
Partners / Managing Directors (Health & Bio Focus)
- James Flynn, MD, PhD - Managing Partner
- Jonathan Leff - Managing Partner
- William Slattery - Managing Partner
- David Clark, PhD - Partner
Other Key Team Members
- Investment team with MD/PhD expertise in drug development
Focus Areas
- Therapeutics
- Oncology
- Neuroscience
- Rare Diseases
- Public Healthcare Equities
- Private Biotech
- Healthcare Services
Notable Exits
- Nuvalent - IPO (2021, NASDAQ: NUVL) - precision oncology
- Horizon Therapeutics - Acquired (2023, by Amgen for $27.8B)
- Multiple biotech IPOs and M&A transactions
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Foundation Medicine | Cambridge, Massachusetts, USA | 2010 | genomics-sequencingdiagnostics+3 |
| Treeline Biosciences | Cambridge, Massachusetts, USA | 2022 | therapeuticsbiotech+3 |
| BridgeBio Oncology Therapeutics | Palo Alto, California, USA | 2015 | biotechoncology+3 |